Compounded · GLP-1

Semaglutide Injection

The most widely prescribed GLP-1 — for good reason.

Semaglutide is the most-studied GLP-1 receptor agonist for weight management. Cypress's compounded semaglutide uses the same active ingredient, prepared per-patient by a state-licensed U.S. pharmacy under the 503A exception. Once-weekly injection, well-understood safety profile, predictable dose escalation.

  • Once-weekly subcutaneous injection — 30 seconds, at home
  • Targets the GLP-1 receptor to support appetite regulation
  • Compounded by a state-licensed U.S. pharmacy
  • Includes clinician oversight, dose escalation, and side-effect support
  • Direct-to-door · cancel anytime on monthly · save more on 6 or 12-month plans
Start your assessment
Compounded semaglutide injection — Cypress Health

Why semaglutide

A first step most women tolerate well.

Compounded semaglutide injection for weight loss

The active ingredient — semaglutide — has been studied extensively for weight management. The dose ramp is gentle, the side-effect profile is well understood, and most women find compounded semaglutide tolerable from the start.

For women in midlife, semaglutide is often the first GLP-1 we recommend. If response plateaus or doesn't reach goals, your clinician can talk through whether tirzepatide or a different protocol might fit better.

Whether semaglutide is right for you depends on your medical history, current medications, and goals. Your clinician will determine that. The intake is the first step.

Dosing & what to expect

A measured start. Adjusted as you go.

1
Weeks 1–4 · Starting dose
0.25 mg once weekly. The starting dose is intentionally low to let your body adjust; mild GI symptoms are common in the first week or two and typically settle.
2
Weeks 5+ · Dose escalation
Your clinician adjusts your dose — typically 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg over time, based on response, tolerance, and goals.
3
Ongoing · Care, not just refills
Your plan includes ongoing clinician oversight, dose adjustment, side-effect support, and lab review when needed.

Side effects & safety

What to know before you start.

Woman reviewing health information at home

Most common: nausea, decreased appetite, mild diarrhea, constipation, fatigue. Typically dose-related and most pronounced in the first week of each new dose.

Less common but important: pancreatitis, gallbladder issues, low blood sugar (especially if you also take insulin or sulfonylureas). Tell your clinician about all current medications.

Muscle mass during treatment: GLP-1 therapy can be associated with loss of lean mass, particularly in women in midlife. Your clinician will discuss strategies to protect muscle — typically resistance training and adequate dietary protein — as part of your care plan.

Not appropriate if: you have a personal or family history of medullary thyroid carcinoma or MEN2; you're pregnant, planning pregnancy, or breastfeeding; or you have severe GI disease or end-stage organ disease.

Compounded medication notice
Compounded semaglutide is dispensed by state-licensed U.S. pharmacies in FDA-regulated facilities under the patient-specific 503A exception. It is not FDA-approved as a finished product. Your clinician will determine whether it is appropriate for your specific health profile.

Clinical evidence

In STEP 1 (Wilding et al., NEJM 2021), injectable semaglutide produced an average ~14.9% body weight loss over 68 weeks at the 2.4 mg weekly dose — the largest published trial of semaglutide for chronic weight management to date.

Compounded semaglutide uses the same active ingredient under the 503A exception. Outcomes from branded clinical trials cannot be directly attributed to compounded preparations.

Questions

Answers to
common questions.

How is compounded semaglutide different from Ozempic or Wegovy?
Same active ingredient, prepared per-patient under the 503A exception — not FDA-approved as a finished product.
Ozempic (for type 2 diabetes) and Wegovy (for weight management) are FDA-approved branded versions of injectable semaglutide manufactured by Novo Nordisk. Compounded semaglutide is prepared per-patient by a state-licensed U.S. pharmacy under the 503A exception — the same active ingredient, but not FDA-approved as a finished product. For some women the branded option is the better fit; for others, compounded is more accessible while remaining clinically appropriate. Your clinician will help you decide.
How quickly should I expect to see results?
Most women notice appetite changes within 1–2 weeks; weight changes typically follow within the first month.
Most women notice appetite changes within the first one to two weeks and start to see scale movement within the first month. The largest published trial of injectable semaglutide for weight management — STEP 1 (Wilding et al., NEJM 2021) — showed an average ~14.9% body weight loss over 68 weeks at the 2.4 mg weekly dose. Outcomes from branded clinical trials cannot be directly attributed to compounded preparations, but the active ingredient is the same. Your individual response depends on dose, time, lifestyle, and biology.
When am I charged?
Not until a clinician confirms your eligibility — typically within 24–48 hours.
You're not charged when you submit your assessment. Your card is securely saved while a licensed clinician reviews your case, typically within 24 to 48 hours. If you're approved, you'll receive an email confirmation before any charge is processed. If you're not approved, you're not charged at all.
How will it ship — and does it need refrigeration?
Cold-chain via UPS or FedEx; refrigerate on arrival.
Once your clinician approves your plan, the pharmacy ships within 1–2 business days via UPS or FedEx, Monday through Friday. Cold-chain shipping is two-day in cooler months and overnight when temperatures are warm. Compounded semaglutide should be refrigerated upon arrival; if it ever arrives frozen, allow it to thaw at room temperature before use. If a shipment is lost or arrives damaged, we'll reship at no cost.
Will I need to stay on treatment after I reach my goal?
Most people regain weight without a structured maintenance plan. We plan that step with you, not around you.
This is one of the most important conversations you'll have with your clinician. The available evidence — including the STEP 4 withdrawal trial (Rubino et al., JAMA 2021) — shows that most people regain weight when they stop GLP-1 therapy without a structured maintenance plan. Some women step down to a lower maintenance dose; some wean off with continued resistance training and protein-forward eating to preserve lean mass; some choose to continue at full dose. There's no single right answer, and the right path is decided with you.
Can I cancel? Will my insurance, HSA, or FSA cover this?
Cancel anytime on monthly. HSA/FSA usually accepted; insurance generally doesn't cover compounded.
The 1-month plan can be cancelled at any time. The 6 and 12-month plans are committed terms billed monthly — you can cancel future renewals after the term ends. Compounded GLP-1 medications are generally not insurance-reimbursable because they're prepared per-patient rather than as FDA-approved finished products. HSA or FSA cards are typically accepted for prescription medications; check with your benefits administrator to confirm eligibility for compounded medications under your specific plan.

See if semaglutide is right for you.

The 3-minute medical screener is free. If you're a candidate, your clinician follows up within 24 hours.

Start your assessment